These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18473851)

  • 41. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy.
    Wang F; Zhang X; Wang Y; Chen Y; Lu H; Meng X; Ye X; Chen W
    Drug Metab Dispos; 2023 May; 51(5):543-559. PubMed ID: 36732076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anthocyanins and their metabolites are weak inhibitors of cytochrome P450 3A4.
    Dreiseitel A; Schreier P; Oehme A; Locher S; Hajak G; Sand PG
    Mol Nutr Food Res; 2008 Dec; 52(12):1428-33. PubMed ID: 18727015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
    Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
    Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
    Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
    Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
    Loos NHC; Beijnen JH; Schinkel AH
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Xenobiotica; 2016 Dec; 46(12):1056-1065. PubMed ID: 26928326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.
    Khan KK; He YQ; Correia MA; Halpert JR
    Drug Metab Dispos; 2002 Sep; 30(9):985-90. PubMed ID: 12167563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
    He K; Woolf TF; Hollenberg PF
    J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors.
    Terkeltaub RA; Furst DE; Digiacinto JL; Kook KA; Davis MW
    Arthritis Rheum; 2011 Aug; 63(8):2226-37. PubMed ID: 21480191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three-dimensional quantitative structure-activity relationship analysis of inhibitors of human and rat cytochrome P4503A enzymes.
    Handa K; Nakagome I; Yamaotsu N; Gouda H; Hirono S
    Drug Metab Pharmacokinet; 2013; 28(4):345-55. PubMed ID: 23358262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
    Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dietary Inhibitors of CYP3A4 Are Revealed Using Virtual Screening by Using a New Deep-Learning Classifier.
    Guttman Y; Kerem Z
    J Agric Food Chem; 2022 Mar; 70(8):2752-2761. PubMed ID: 35104412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of in vitro cytochrome P450 induction and inhibition activity of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber L.
    Koe XF; Lim EL; Seah TC; Amanah A; Wahab HA; Adenan MI; Sulaiman SF; Tan ML
    Food Chem Toxicol; 2013 Oct; 60():98-108. PubMed ID: 23876819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies.
    Molden E; Garcia BH; Braathen P; Eggen AE
    Eur J Clin Pharmacol; 2005 Apr; 61(2):119-25. PubMed ID: 15692832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
    Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
    Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-Walled Carbon Nanotubes Inhibit the Cytochrome P450 Enzyme, CYP3A4.
    El-Sayed R; Bhattacharya K; Gu Z; Yang Z; Weber JK; Li H; Leifer K; Zhao Y; Toprak MS; Zhou R; Fadeel B
    Sci Rep; 2016 Feb; 6():21316. PubMed ID: 26899743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Uncertainty-Guided Deep Learning Method Facilitates Rapid Screening of CYP3A4 Inhibitors.
    Wang R; Liu Z; Gong J; Zhou Q; Guan X; Ge G
    J Chem Inf Model; 2023 Dec; 63(24):7699-7710. PubMed ID: 38055780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.
    Rougée LRA; Mohutsky MA; Bedwell DW; Ruterbories KJ; Hall SD
    Drug Metab Dispos; 2017 Sep; 45(9):1008-1018. PubMed ID: 28679672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.